SUMM.L Regulatory News (SUMM)

SUMM.L Information

There is currently no data for SUMM

REMOVE ADS

Date		Source	Headline
3rd Apr 2019	12:00 pm	GNW	Summit’s Pipeline Expands with Series of New Mechanism Antibiotics Targeting Enterobacteriaceae
2nd Apr 2019	12:00 pm	GNW	Summit Therapeutics to Present at H. C. Wainwright & Co. Global Life Sciences Conference
29th Mar 2019	5:45 pm	GNW	Award of Share Options
29th Mar 2019	11:15 am	GNW	Filing of Annual Report on Form 20-F
27th Mar 2019	11:00 am	GNW	Final Results
25th Mar 2019	11:00 am	GNW	Notice of Results
18th Mar 2019	11:00 am	GNW	Summit Therapeutics to Present at Upcoming Conferences
14th Mar 2019	11:00 am	GNW	Summit Highlights Use of Discuva Platform in Identifying New Mechanism Antibiotics against Neisseria Gonorrhoeae and ESKAPE Pathogens at Novel Antimicrobials and AMR Diagnostics 2019 Conference
25th Feb 2019	12:00 pm	GNW	Summit’s SMT-571 Potent Against Over 200 Clinical Isolates of Neisseria Gonorrhoeae, Including Numerous Multi- and Extensively-Drug Resistant Strains, in Published Preclinical Data
13th Feb 2019	12:00 pm	GNW	Summit Doses First Patient in Phase 3 Clinical Trials of Precision Antibiotic Ridinilazole for C. Difficile Infection
8th Feb 2019	12:00 pm	GNW	Summit Therapeutics to Present at the BIO CEO & Investor Conference
15th Jan 2019	5:45 pm	GNW	Holding(s) in Company
14th Jan 2019	12:00 pm	GNW	Award of Restricted Stock Units
10th Jan 2019	4:15 pm	GNW	Holding(s) in Company
10th Jan 2019	11:30 am	GNW	Holding(s) in Company
10th Jan 2019	7:00 am	GNW	Completion of $25 million Subscription
9th Jan 2019	4:45 pm	GNW	Holding(s) in Company
8th Jan 2019	7:00 am	GNW	Update on Admission
4th Jan 2019	12:30 pm	GNW	Result of General Meeting
2nd Jan 2019	9:40 am	GNW	Holding(s) in Company
18th Dec 2018	12:15 pm	GNW	Holding(s) in Company
17th Dec 2018	7:05 am	GNW	Proposed Subscription to Raise $25m and Notice of General Meeting
17th Dec 2018	7:00 am	GNW	Summit Therapeutics Announces Departure of Chief Financial Officer
11th Dec 2018	12:00 pm	GNW	3rd Quarter Results
6th Dec 2018	12:00 pm	GNW	Summit Therapeutics to Report Financial Results for the Third Quarter and Nine Months Ended 31 October 2018 on 11 December 2018
30th Nov 2018	1:30 pm	GNW	Holding(s) in Company
12th Nov 2018	12:00 pm	GNW	Summit Highlights Importance of Innovation in Fight Against Antibiotic Resistance During Antibiotics Awareness Week
12th Nov 2018	7:00 am	GNW	Appointment of Joint Broker
7th Nov 2018	12:00 pm	GNW	Summit Therapeutics to Participate in Jefferies 2018 London Healthcare Conference
1st Nov 2018	4:34 pm	GNW	Holding(s) in Company
1st Nov 2018	11:00 am	GNW	Summit Recognises C. difficile Awareness Month
24th Oct 2018	4:15 pm	GNW	Director/PDMR Shareholding
22nd Oct 2018	7:00 am	GNW	Award of Share Options
20th Sep 2018	12:00 pm	GNW	Summit Reports Financial Results for the Second Quarter Ended 31 July 2018 and Operational Progress
27th Dec 2017	7:00 am	RNS	Acquisition of Discuva Ltd
10th May 2012	2:04 pm	RNS	Grant of Options
30th Dec 2009	11:07 am	RNS	Result of GM
30th Dec 2009	7:00 am	RNS	Result of Placing and Open Offer
11th Dec 2009	12:53 pm	RNS	Placing and Open Offer and Appointment of NOMAD
11th Dec 2009	12:40 pm	RNS	Wellcome Trust Grant
31st Jan 2008	7:00 am	RNS	Trading Statement
16th Jan 2008	7:01 am	RNS	Start of Ph II clinical trial
6th Dec 2007	7:00 am	RNS	Change of Adviser
5th Nov 2007	11:18 am	RNS	Director/PDMR Shareholding
30th Oct 2007	7:02 am	RNS	Re Agreement
30th Oct 2007	7:01 am	RNS	Interim Results
25th Oct 2007	4:07 pm	RNS	Holding in Company
23rd Oct 2007	7:02 am	RNS	Clinical Update
12th Oct 2007	9:00 am	RNS	Notice of Results
2nd Oct 2007	7:01 am	RNS	Research Donation

Latest Share Chat

SUMM.L Regulatory News (SUMM)

Please enter at least 2 characters

No results found

Search results

Recently viewed

Trending